FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1583421095> ?p ?o ?g. }

• W1583421095 endingPage "12047" @default.
• W1583421095 startingPage "12035" @default.
• W1583421095 abstract "// Friederike Braig 1 , Manuela März 1 , Aneta Schieferdecker 1 , Alexander Schulte 2 , Mareike Voigt 1 , Alexander Stein 1 , Tobias Grob 3 , Malik Alawi 4 , Daniela Indenbirken 5 , Malte Kriegs 6 , Erik Engel 7 , Udo Vanhoefer 8 , Adam Grundhoff 5 , Sonja Loges 1,9 , Kristoffer Riecken 10 , Boris Fehse 10 , Carsten Bokemeyer 1 and Mascha Binder 1 1 Department of Oncology and Hematology, BMT with section Pneumology, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2 Department of Neurosurgery, Laboratory for Brain Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 3 Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 4 Bioinformatics Service Facility, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 5 Heinrich-Pette-Institute, Leibniz-Institute for Experimental Virology (HPI), Hamburg, Germany 6 Radiation Biology and Radio-Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 7 Hämatologisch-onkologische Praxis Altona (HOPA), Hamburg, Germany 8 Marienkrankenhaus, Zentrum für Innere Medizin, Hamburg, Germany 9 Institute for Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 10 Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Correspondence to: Mascha Binder, email: // Keywords : panitumumab, cetuximab, EGFR antibody resistance, mutation, circulating tumor DNA Received : January 30, 2015 Accepted : February 20, 2015 Published : March 14, 2015 Abstract Acquired resistance to epidermal growth factor receptor (EGFR) targeted antibodies represents a clinical challenge in the treatment of gastrointestinal tumors such as metastatic colorectal cancer, but its molecular mechanisms are incompletely understood. We scanned KRAS exon 2/3/4, NRAS exon 2/3/4 and the overlapping epitopes of the EGFR antibodies cetuximab and panitumumab for mutations in pre- and post-treatment tumor tissue of 21 patients with gastrointestinal cancer treated with chemotherapy +/- EGFR antibodies by next-generation sequencing (“tumor tissue” cohort). We describe a novel EGFR exon 12 mutation acquired in tumors of 1 out of 3 patients treated with panitumumab. The EGFR G465R mutation introduces a positive charge within the overlap of the panitumumab and cetuximab epitopes. It abrogates antibody binding and mediates cross-resistance to both antibodies in EGFR G465R-transfected Ba/F3 cells. In circulating tumor DNA from an independent “liquid biopsy” cohort of 27 patients, we found this novel mutation in 1 out of 6 panitumumab-treated cases while about one third of patients show acquired RAS mutations. We show that acquired resistance by epitope-changing mutations also emerges during panitumumab treatment, which can be easily detected by a liquid biopsy approach even before clinical resistance occurs and this may help in tailoring EGFR-targeted therapies." @default.
• W1583421095 created "2016-06-24" @default.
• W1583421095 creator A5002896795 @default.
• W1583421095 creator A5003684059 @default.
• W1583421095 creator A5016465020 @default.
• W1583421095 creator A5022181207 @default.
• W1583421095 creator A5023889912 @default.
• W1583421095 creator A5044226814 @default.
• W1583421095 creator A5044594852 @default.
• W1583421095 creator A5045778623 @default.
• W1583421095 creator A5051305853 @default.
• W1583421095 creator A5052933885 @default.
• W1583421095 creator A5066665601 @default.
• W1583421095 creator A5067320487 @default.
• W1583421095 creator A5077205301 @default.
• W1583421095 creator A5078383767 @default.
• W1583421095 creator A5084086757 @default.
• W1583421095 creator A5084999115 @default.
• W1583421095 creator A5089296981 @default.
• W1583421095 creator A5090322270 @default.
• W1583421095 date "2015-03-14" @default.
• W1583421095 modified "2023-09-30" @default.
• W1583421095 title "Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer" @default.
• W1583421095 cites W1538989751 @default.
• W1583421095 cites W1931270562 @default.
• W1583421095 cites W1981804005 @default.
• W1583421095 cites W1997257161 @default.
• W1583421095 cites W2005348280 @default.
• W1583421095 cites W2006168411 @default.
• W1583421095 cites W2036045525 @default.
• W1583421095 cites W2041921050 @default.
• W1583421095 cites W2053439872 @default.
• W1583421095 cites W2057623977 @default.
• W1583421095 cites W2062109911 @default.
• W1583421095 cites W2085633477 @default.
• W1583421095 cites W2095201384 @default.
• W1583421095 cites W2097121246 @default.
• W1583421095 cites W2097924418 @default.
• W1583421095 cites W2098354753 @default.
• W1583421095 cites W2102953577 @default.
• W1583421095 cites W2103789431 @default.
• W1583421095 cites W2104580737 @default.
• W1583421095 cites W2106789440 @default.
• W1583421095 cites W2107503225 @default.
• W1583421095 cites W2109897646 @default.
• W1583421095 cites W2114327118 @default.
• W1583421095 cites W2116731538 @default.
• W1583421095 cites W2139119404 @default.
• W1583421095 cites W2142564546 @default.
• W1583421095 cites W2143574474 @default.
• W1583421095 cites W2144025124 @default.
• W1583421095 cites W2144425748 @default.
• W1583421095 cites W2152362765 @default.
• W1583421095 cites W2155311724 @default.
• W1583421095 cites W2156700619 @default.
• W1583421095 cites W2164837623 @default.
• W1583421095 cites W2165411051 @default.
• W1583421095 cites W2166559675 @default.
• W1583421095 cites W2171237493 @default.
• W1583421095 cites W2409420104 @default.
• W1583421095 cites W4234746319 @default.
• W1583421095 cites W4235642752 @default.
• W1583421095 cites W4376848401 @default.
• W1583421095 cites W4385789423 @default.
• W1583421095 cites W93307583 @default.
• W1583421095 doi "https://doi.org/10.18632/oncotarget.3574" @default.
• W1583421095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4494921" @default.
• W1583421095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26059438" @default.
• W1583421095 hasPublicationYear "2015" @default.
• W1583421095 type Work @default.
• W1583421095 sameAs 1583421095 @default.
• W1583421095 citedByCount "52" @default.
• W1583421095 countsByYear W15834210952015 @default.
• W1583421095 countsByYear W15834210952016 @default.
• W1583421095 countsByYear W15834210952017 @default.
• W1583421095 countsByYear W15834210952018 @default.
• W1583421095 countsByYear W15834210952019 @default.
• W1583421095 countsByYear W15834210952020 @default.
• W1583421095 countsByYear W15834210952021 @default.
• W1583421095 countsByYear W15834210952022 @default.
• W1583421095 countsByYear W15834210952023 @default.
• W1583421095 crossrefType "journal-article" @default.
• W1583421095 hasAuthorship W1583421095A5002896795 @default.
• W1583421095 hasAuthorship W1583421095A5003684059 @default.
• W1583421095 hasAuthorship W1583421095A5016465020 @default.
• W1583421095 hasAuthorship W1583421095A5022181207 @default.
• W1583421095 hasAuthorship W1583421095A5023889912 @default.
• W1583421095 hasAuthorship W1583421095A5044226814 @default.
• W1583421095 hasAuthorship W1583421095A5044594852 @default.
• W1583421095 hasAuthorship W1583421095A5045778623 @default.
• W1583421095 hasAuthorship W1583421095A5051305853 @default.
• W1583421095 hasAuthorship W1583421095A5052933885 @default.
• W1583421095 hasAuthorship W1583421095A5066665601 @default.
• W1583421095 hasAuthorship W1583421095A5067320487 @default.
• W1583421095 hasAuthorship W1583421095A5077205301 @default.
• W1583421095 hasAuthorship W1583421095A5078383767 @default.
• W1583421095 hasAuthorship W1583421095A5084086757 @default.
• W1583421095 hasAuthorship W1583421095A5084999115 @default.

• next